Biotechnology Contract Manufacturing Market by Service (Manufacturing, Fill Finish, Packaging), Type (Drug Substance, Drug Product), Scale, Source (Mammalian), Therapy Area (Oncology), Molecule Type (mAbs, ADC, CGT, Vaccines) - Global Forecasts to 2028

Biotechnology Contract Manufacturing Market by Service (Manufacturing, Fill Finish, Packaging), Type (Drug Substance, Drug Product), Scale, Source (Mammalian), Therapy Area (Oncology), Molecule Type (mAbs, ADC, CGT, Vaccines) - Global Forecasts to 2028

The biotechnology contract manufacturing market is estimated to reach USD 24.8 billion by 2028 from USD 16.6 billion in 2023, at a CAGR of 8.3% during the forecast period of 2023 to 2028. The growth of this market can be attributed to the increasing partnerships and collaborations between pharmaceutical companies and biologics contract manufacturers. For instance, In January 2023, Catalent (US) entered into an agreement with Sarepta Therapeutics, Inc. (US) for manufacturing of Sarepta’s most advanced gene therapy candidate, delandistrogene moxeparvovec (SRP-9001) for the treatment of Duchenne muscular dystrophy. Similarly, In December 2022, Merck KGaA (Germany) and Synplogen (Japan) entered into an agreement to accelerate the development and manufacturing of viral vector-based gene therapy applications.

“The monoclonal antibodies segment accounted for the largest share by molecule type during the forecast period.”

In 2022, the monoclonal antibodies segment accounted for the largest share by molecules in the global biotechnology contract manufacturing market. The large share of this segment is attributed to the rising prevalence of diseases, increasing government initiatives for the development of monoclonal antibody drugs, and the growing number of mAb product candidates currently in the clinical pipeline.

“Europe: The second largest region in the biotechnology contract manufacturing market”

Europe accounted for the second-largest market for biotechnology contract manufacturing market after North America. The European biotechnology contract manufacturing market has experienced substantial growth in recent years, driven by various factors such as increasing investments for the development of biologics such as monoclonal antibodies and cell & gene therapies and biomanufacturing capacity expansions. Europe is at the forefront of developing and adopting emerging technologies in the field of biotechnology contract manufacturing market. In March 2023, Lonza completed its cGMP clinical and commercial manufacturing site, which is dedicated to large-scale commercial drug product manufacturing.

The primary interviews conducted for this report can be categorized as follows:

By Respondent: Supply Side - 70% and Demand Side - 30%

By Designation: Managers - 45%, CXO and Directors - 30%, and Executives - 25%

By Region: North America - 40%, Europe - 25%, Asia-Pacific - 20%, Latin America - 10% and Middle East & Africa - 5%

List of Companies Profiled in the Report:

Lonza (Switzerland)

Thermo Fisher Scientific Inc. (US)

Catalent, Inc. (US)

Samsung Biologics (South Korea)

WuXi Biologics (China)

Boehringer Ingelheim International GmbH (Germany)

FUJIFILM Holdings Corporation (Japan)

AbbVie, Inc. (US)

Eurofins Scientific (Luxembourg)

GenScript Biotech Corporation (US)

AGC, Inc. (Japan)

Merck KGaA (Germany)

JSR Corporation (Japan)

Stelis (India)

Recipharm AB (Sweden)

Emergent (US)

Shanghai Fosun Pharmaceutical Co., Ltd. (China)

LOTTE BIOLOGICS (South Korea)

Hepalink Group (China)

Curia Global, Inc. (US)

JRS Pharma (Germany)

MINAPHARM Pharmaceuticals (Egypt)

Rentschler Biopharma SE (Germany)

Avid Bioservices, Inc. (US)

Abzena Ltd. (US)

Polyplus Transfection (Germany)

Midas Pharma GmbH (Germany)

MabPlex International Co., Ltd. (China)

Asahi Kasei Corporation (Japan)

Research Coverage:

This report provides a detailed picture of the biotechnology contract manufacturing market. It aims to estimate the size and future growth potential of the market across different segments such as the service, type, scale of operation, source, molecule type, therapeutic area, and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

Analysis of key drivers (Increasing demand for biologics & biosimilars, Increased biologics outsourcing trend among biopharmaceutical companies, Increased focus on personalized medicine, Increasing partnerships and collaborations between pharmaceutical companies and biologics CDMOs), restraints (intellectual property rights issues), opportunities (Rising demand for cell & gene therapy, biologics contract manufacturing market expansions in emerging countries, expansion of biologics manufacturing capacities by CMOs, strong emphasis on drug development), and challenges (challenges to meet reformed regulations) influencing the growth of the market.

Service Development/Innovation: Detailed insights on upcoming technologies, research & development activities in the biotechnology contract manufacturing market

Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.

Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the biotechnology contract manufacturing market

Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like Lonza (Switzerland), Thermo Fisher Scientific Inc. (US), Catalent, Inc. (US), WuXi Biologics (China), AbbVie, Inc. (US), and others in the market.